Eltrombopag: Introduction to the drug used to treat thrombocytopenia

Eltrombopag (Eltrombopag) is an oral, non-peptide thrombopoietin receptor agonist, mainly used to treat thrombocytopenia.

The main active ingredient of Eltrombopag is Eltrombopag ethanolamine, which is usually in tablet form and should be used according to the instructions of your doctor. It is mainly used to treat thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura (ITP) who have failed treatment with glucocorticoids and immune globulin or who have undergone splenectomy. In addition, it is approved for the treatment of patients with severe aplastic anemia who are refractory to immunosuppressive therapy.

For most patients, the recommended starting dose is 25 mg taken once daily on an empty stomach (one hour before or two hours after a meal). Based on platelet count and patient response, the dose may be adjusted up to a maximum of 75 mg daily. In patients with moderate or severe hepatic impairment, the starting dose should be reduced to 25 mg once daily. After initiation of treatment, platelet counts should be monitored regularly and dosage adjusted as needed. Dosage adjustments should be made according to the doctor's recommendations and the patient's response should be observed.

Eltrombopag interacts with the transmembrane domain of the human thrombopoietin receptor (TPO-R) to initiate a signaling cascade, inducing the proliferation and differentiation of bone marrow progenitor cells into megakaryocytes, thereby promoting platelet production. This mechanism makes eltrombopag significantly effective in increasing platelet counts.

Eltrombopag has shown promising efficacy in the treatment of thrombocytopenia. It can significantly increase the patient's platelet count and reduce or prevent bleeding events caused by thrombocytopenia. For ITP patients and patients with severe aplastic anemia, eltrombopag can improve their clinical symptoms and prognosis.

Although eltrombopag is effective in raising platelet counts, it may also cause some side effects. Common side effects include headache, nausea, diarrhea, muscle pain, etc. A small number of patients may experience serious adverse reactions, such as liver toxicity, thrombosis, etc. Therefore, during the use of eltrombopag, the patient's liver function, platelet count and other indicators should be regularly monitored, and the patient's response should be observed.

Before using eltrombopag, patients should undergo a comprehensive evaluation, including routine blood tests, liver and kidney function tests, etc. Eltrombopag should be used with caution in patients with severe hepatic impairment or renal impairment.

Eltrombopag may interact with other medications, affecting their effectiveness or increasing the risk of side effects. Therefore, concomitant use of medications that may affect its efficacy or increase the risk of side effects should be avoided while using eltrombopag.

During the use of eltrombopag, the patient's platelet count, liver function and other indicators should be regularly monitored, and the patient's response should be observed. If discomfort or side effects worsen, you should seek medical treatment promptly and adjust the treatment plan.

For elderly patients, the dose and usage of eltrombopag should be adjusted according to their liver and kidney function and physical condition. The safety and effectiveness of eltrombopag in children have not been established and its use in pediatric patients is not recommended. The safety and effectiveness of eltrombopag in pregnant and breastfeeding women have not been established and should be used with caution. If it must be used, it should be done under the guidance of a doctor.